Lung cancer Patients' own immune cells could shrink tumors in new trial
NCT ID NCT07560111
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This phase II trial tests a treatment called GC101 TIL, which uses immune cells taken from a patient's own lung tumor. These cells are grown in a lab and then infused back into the patient to attack the cancer. The study involves 28 adults with non-small cell lung cancer who have not responded to standard treatments. The main goal is to see if the treatment shrinks tumors and delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.